Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Sort descending Date Submission Received Date Recommendation Issued
Perjeta Herceptin Combo Pack Pertuzumab Metastatic Breast Cancer Reimburse with clinical criteria and/or conditions Complete
Perjeta or Perjeta-Herceptin Combo Pack Pertuzumab Neoadjuvant Breast Cancer Do not reimburse Complete
Pomalyst Pomalidomide Multiple Myeloma Reimburse with clinical criteria and/or conditions Complete
Proleukin Aldesleukin (IL-2) In-transit Melanoma Reimburse Complete
Revlimid Lenalidomide Multiple Myeloma (as maintenance therapy) Reimburse with clinical criteria and/or conditions Complete
Stivarga (CRC) Regorafenib Metastatic Colorectal Cancer Do not reimburse Complete
Stivarga (GIST) Regorafenib Gastrointestinal Stromal Tumour Reimburse with clinical criteria and/or conditions Complete
Stivarga Resubmission (CRC) Regorafenib Metastatic Colorectal Cancer Do not reimburse Complete
Sutent Sunitinib malate Pancreatic Neuroendocrine Tumour Reimburse with clinical criteria and/or conditions Complete
Sylvant Siltuximab Multicentric Castleman's disease (MCD) Reimburse with clinical criteria and/or conditions Complete